NCT06933043View on ClinicalTrials.gov

A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults.

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

August 1, 2025

Study Completion Date

November 8, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

NAV-240

Three doses of intravenous (IV) low dose, medium dose or high dose NAV-240 will be administered to participants.

DRUG

Placebo

Three doses of matching placebo will be administered to participants.

Trial Locations (1)

4006

RECRUITING

Nucleus Network, Brisbane

Sponsors

Collaborators (1)

Navigator Medicines, Inc.
All Listed Sponsors
collaborator

Navigator Medicines, Inc.

INDUSTRY

lead

Southern Star Research

INDUSTRY

NCT06933043 - A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults. | Biotech Hunter | Biotech Hunter